CD19 and B-cell chronic lymphocytic leukemia: In summary, response to two separate CD19 CAR-T therapy products (Kymriah and Yescarta) in three indications (CLL, ALL and LBCL) is at least partially predetermined by functional attributes of the CAR-T infusion product.